M
Manel Sabaté
Researcher at University of Barcelona
Publications - 607
Citations - 26779
Manel Sabaté is an academic researcher from University of Barcelona. The author has contributed to research in topics: Stent & Myocardial infarction. The author has an hindex of 63, co-authored 549 publications receiving 23775 citations. Previous affiliations of Manel Sabaté include Complutense University of Madrid & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial.
Fernando Alfonso,Rafael Melgares,Vicente Mainar,Román Lezaún,Nicolás Vázquez,Juan Carlos Tascón,Francisco Pomar,Angel Cequier,Juan Angel,Maria-José Pérez-Vizcayno,Manel Sabaté,Camino Bañuelos,Cristina Fernández,José Mota García +13 more
TL;DR: In patients with EDG ISR, repeat stent implantation provides better clinical and angiographic outcome than conventional balloon angioplasty and constitutes a specific subgroup with relevant therapeutic implications.
Journal ArticleDOI
Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results.
Stephen G. Ellis,Tommaso Gori,Patrick W. Serruys,Holger Nef,Giuseppe Steffenino,Salvatore Brugaletta,Thomas Münzel,Cordula Feliz,Götz Schmidt,Manel Sabaté,Yoshinobu Onuma,R.J. Van Geuns,Run Lin Gao,Maurizio Menichelli,Dean J. Kereiakes,Gregg W. Stone,Luca Testa,Takeshi Kimura,Alexandre Abizaid +18 more
TL;DR: In the present analysis, the largest to date of its type, relative scaffold undersizing was the strongest determinant of VLST, and likely has ramifications for all bioresorbable scaffolds.
Journal ArticleDOI
Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?
Journal ArticleDOI
Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial.
Josep Gomez-Lara,Luis Ortega-Paz,Salvatore Brugaletta,Javier Cuesta,Sebastián Romaní,Antonio Serra,Pablo Salinas,Bruno García del Blanco,Javier Goicolea,Rosana Hernández-Antolín,Paula Antuña,Rafael Romaguera,Ander Regueiro,Fernando Rivero,Angel Cequier,Fernando Alfonso,Joan Antoni Gómez-Hospital,Manel Sabaté +17 more
TL;DR: The MAGSTEMI trial showed larger angiographic lumen loss and restenosis with Magnesium-based bioresorbable scaffold (MgBRS) than with sirolimus-eluting stent (SES) and further generations of MgB RS should prolong the radial force.
Journal ArticleDOI
Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent Two-Year Final Clinical Results
Yoshitaka Shiratori,Clarissa Cola,Salvatore Brugaletta,Luis Alvarez-Contreras,Victoria Martin-Yuste,Bruno García del Blanco,Rafael Ruiz-Salmerón,José F. Díaz,Eduardo Pinar,Vicens Martí,Juan García-Picart,Manel Sabaté +11 more
TL;DR: Compared with PB-PES, PF-P ES was associated with increased neointimal proliferation and subsequent clinical restenosis and Polymer plays an essential role in the performance of drug-eluting stents.